Free Access
Med Sci (Paris)
Volume 30, Number 4, Avril 2014
Page(s) 452 - 461
Section Microenvironnements tumoraux : conflictuels et complémentaires
Published online 05 May 2014
  1. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004 ; 22 : 247–306. [CrossRef] [PubMed] [Google Scholar]
  2. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013 ; 122 : 872–884. [CrossRef] [PubMed] [Google Scholar]
  3. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010 ; 11 : 1029–1035. [CrossRef] [PubMed] [Google Scholar]
  4. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011 ; 118 : 3657–3660. [CrossRef] [PubMed] [Google Scholar]
  5. Li L, Bhatia R. Stem cell quiescence. Clin Cancer Res 2011 ; 17 : 4936–4941. [CrossRef] [PubMed] [Google Scholar]
  6. Faubert A, Chagraoui J, Mayotte N, et al. Complementary and independent function for Hoxb4 and Bmi1 in HSC activity. Cold Spring Harb Symp Quant Biol 2008 ; 73 : 555–564. [CrossRef] [PubMed] [Google Scholar]
  7. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978 ; 4 : 7–25. [PubMed] [Google Scholar]
  8. Lataillade JJ, Brunet de La Grange P, Uzan G, Le Bousse-Kerdiles MC. Les cellules souches ont-elles l’âge de leur niche ? À la recherche d’un sérum de jouvence. Med Sci (Paris) 2010 ; 26 : 582–585. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  9. Kiel MJ, Morrison SJ. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol 2008 ; 8 : 290–301. [CrossRef] [PubMed] [Google Scholar]
  10. Frenette PS, Pinho S, Lucas D, Scheiermann C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu Rev Immunol 2013 ; 31 : 285–316. [CrossRef] [PubMed] [Google Scholar]
  11. Rizo A, Vellenga E, de Haan G, Schuringa JJ. Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? Hum Mol Genet 2006 ; 15 (suppl 2) : R210–R219. [CrossRef] [PubMed] [Google Scholar]
  12. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006 ; 6 : 93–106. [CrossRef] [PubMed] [Google Scholar]
  13. Gordon MY, Dowding CR, Riley GP, et al. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987 ; 328 : 342–344. [CrossRef] [PubMed] [Google Scholar]
  14. Verfaillie CM, McCarthy JB, McGlave PB. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 1992 ; 90 : 1232–1241. [CrossRef] [PubMed] [Google Scholar]
  15. Salgia R, Quackenbush E, Lin J, et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood 1999 ; 94 : 4233–4246. [PubMed] [Google Scholar]
  16. Geay JF, Buet D, Zhang Y, et al. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 2005 ; 65 : 2676–2683. [CrossRef] [PubMed] [Google Scholar]
  17. Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006 ; 12 : 1175–1180. [CrossRef] [PubMed] [Google Scholar]
  18. Flamant S, Kortulewski T, Dugray A, et al. Osteopontin is upregulated by BCR-ABL. Biochem Biophys Res Commun 2005 ; 333 : 1378–1384. [CrossRef] [PubMed] [Google Scholar]
  19. Bhatia R, McCarthy JB, Verfaillie CM. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 1996 ; 87 : 3883–3891. [PubMed] [Google Scholar]
  20. Bhatia R, Munthe HA, Verfaillie CM. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Leukemia 1998 ; 12 : 1708–1717. [CrossRef] [PubMed] [Google Scholar]
  21. Jin L, Tabe Y, Konoplev S, et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 2008 ; 7 : 48–58. [CrossRef] [PubMed] [Google Scholar]
  22. Schepers K, Pietras EM, Reynaud D, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 2013 ; 13 : 285–299. [CrossRef] [PubMed] [Google Scholar]
  23. Schmidt T, Kharabi Masouleh B, Loges S, et al. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell 2011 ; 19 : 740–753. [CrossRef] [PubMed] [Google Scholar]
  24. Yamamoto-Sugitani M, Kuroda J, Ashihara E, et al. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci USA 2011 ; 108 : 17468–17473. [CrossRef] [Google Scholar]
  25. Laperrousaz B, Jeanpierre S, Sagorny K, et al. Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression. Blood 2013 ; 122 : 3767–3777. [CrossRef] [PubMed] [Google Scholar]
  26. Nair RR, Tolentino J, Hazlehurst LA. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol 2010 ; 80 : 602–612. [CrossRef] [PubMed] [Google Scholar]
  27. Nwajei F, Konopleva M., The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv Hematol 2013 ; 2013 : 953982. [CrossRef] [PubMed] [Google Scholar]
  28. Krause DS, Scadden DT, Preffer FI. The hematopoietic stem cell niche: home for friend and foe? Cytometry B Clin Cytom 2013 ; 84 : 7–20. [CrossRef] [PubMed] [Google Scholar]
  29. Forkner CE, Scott TF. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1931 ; 97 : 3–5. [CrossRef] [Google Scholar]
  30. Guo-Bao W, Xiao-Qin C, Qi-Rong G, et al. Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta1-integrin in K562 chronic myelogenous leukemia cell line. Leuk Lymphoma 2010 ; 51 : 1090–1097. [CrossRef] [PubMed] [Google Scholar]
  31. Agarwal A, Fleischman AG, Petersen CL, et al. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood 2012 ; 120 : 2658–2668. [CrossRef] [PubMed] [Google Scholar]
  32. Weisberg E, Azab AK, Manley PW, et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 2012 ; 26 : 985–990. [CrossRef] [PubMed] [Google Scholar]
  33. Galaup A, Germain S. Les anticorps anti-PlGF. Un nouvel outil thérapeutique anti-angiogénique ? Med Sci (Paris) 2008 ; 24 : 459–462. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  34. Boyerinas B, Zafrir M, Yesilkanal AE, et al. Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood 2013 ; 121 : 4821–4831. [CrossRef] [PubMed] [Google Scholar]
  35. Nilsson SK, Haylock DN, Johnston HM, et al. Hyaluronan is synthesized by primitive hemopoietic cells, participates in their lodgment at the endosteum following transplantation, and is involved in the regulation of their proliferation and differentiation in vitro. Blood 2003 ; 101 : 856–862. [CrossRef] [PubMed] [Google Scholar]
  36. Arai F, Hirao A, Ohmura M, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004 ; 118 : 149–161. [CrossRef] [PubMed] [Google Scholar]
  37. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003 ; 425 : 836–841. [CrossRef] [PubMed] [Google Scholar]
  38. Bhatia M, Bonnet D, Wu D, et al. Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. J Exp Med 1999 ; 189 : 1139–1148. [CrossRef] [PubMed] [Google Scholar]
  39. Adams GB, Chabner KT, Alley IR, et al. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 2006 ; 439 : 599–603. [CrossRef] [PubMed] [Google Scholar]
  40. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006 ; 25 : 977–988. [CrossRef] [PubMed] [Google Scholar]
  41. Itkin T, Kaufmann KB, Gur-Cohen S, et al. Fibroblast growth factor signaling promotes physiological bone remodeling and stem cell self-renewal. Curr Opin Hematol 2013 ; 20 : 237–244. [PubMed] [Google Scholar]
  42. Teixido J, Hemler ME, Greenberger JS, Anklesaria P. Role of beta 1 and beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma. J Clin Invest 1992 ; 90 : 358–367. [CrossRef] [PubMed] [Google Scholar]
  43. Pruijt JF, van Kooyk Y, Figdor CG, et al. Anti-LFA-1 blocking antibodies prevent mobilization of hematopoietic progenitor cells induced by interleukin-8. Blood 1998 ; 91 : 4099–4105. [PubMed] [Google Scholar]
  44. Mancini SJ, Mantei N, Dumortier A, et al. Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation. Blood 2005 ; 105 : 2340–2342. [CrossRef] [PubMed] [Google Scholar]
  45. Kikushige Y, Yoshimoto G, Miyamoto T, et al. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol 2008 ; 180 : 7358–7367. [CrossRef] [PubMed] [Google Scholar]
  46. Arai F, Hosokawa K, Toyama H, et al. Role of N-cadherin in the regulation of hematopoietic stem cells in the bone marrow niche. Ann NY Acad Sci 2012 ; 1266 : 72–77. [CrossRef] [Google Scholar]
  47. Nilsson SK, Johnston HM, Whitty GA, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 2005 ; 106 : 1232–1239. [CrossRef] [PubMed] [Google Scholar]
  48. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003 ; 425 : 841–846. [CrossRef] [PubMed] [Google Scholar]
  49. Kovach NL, Lin N, Yednock T, et al. Stem cell factor modulates avidity of alpha 4 beta 1 and alpha 5 beta 1 integrins expressed on hematopoietic cell lines. Blood 1995 ; 85 : 159–167. [PubMed] [Google Scholar]
  50. Driessen RL, Johnston HM, Nilsson SK. Membrane-bound stem cell factor is a key regulator in the initial lodgment of stem cells within the endosteal marrow region. Exp Hematol 2003 ; 31 : 1284–1291. [CrossRef] [PubMed] [Google Scholar]
  51. Bhardwaj G, Murdoch B, Wu D, et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol 2001 ; 2 : 172–180. [CrossRef] [PubMed] [Google Scholar]
  52. Dimitroff CJ, Lee JY, Rafii S, et al. CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol 2001 ; 153 : 1277–1286. [CrossRef] [PubMed] [Google Scholar]
  53. Yamazaki S, Ema H, Karlsson G, et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 2011 ; 147 : 1146–1158. [CrossRef] [PubMed] [Google Scholar]
  54. Yoshihara H, Arai F, Hosokawa K, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 2007 ; 1 : 685–697. [CrossRef] [PubMed] [Google Scholar]
  55. Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003 ; 423 : 409–414. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.